Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Rona YaegerDaisuke KotaniSebastián MondacaAparna R ParikhHideaki BandoEmily E Van SeventerHiroya TaniguchiHuiYong ZhaoClaire N ThantElisa de StanchinaNeal X RosenRyan B CorcoranTakayuki YoshinoZhan YaoHiromichi EbiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Response to EGFR antibody treatment in mCRCs with class 2 BRAF mutants is rare, while a large portion of CRCs with class 3 BRAF mutants respond. Patients with colorectal cancer with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment.See related commentary by Fontana and Valeri, p. 6896.